Online Inquiry
Dacomitinib (PF-00299804)
SPC-00648
CAS No. 1110813-31-4
| Size | Price |
| 10 mM (1 mL in DMSO) | Online Inquiry |
| 5 mg | Online Inquiry |
| 10 mg | Online Inquiry |
| 50 mg | Online Inquiry |
| 200 mg | Online Inquiry |
| Bulk Size | Online Inquiry |
EGFR inhibitor ; HER2 inhibitor ; Apoptosis related activator
| Description |
|---|
| Dacomitinib (PF299804, PF299) is a potent, irreversible pan-ErbB inhibitor, mostly to EGFR with IC50 of 6 nM in a cell-free assay. Dacomitinib inhibits ERBB2 and ERBB4 with IC50 of 45.7 nM and 73.7 nM, respectively. Dacomitinib is effective against NSCLCs with EGFR or ERBB2 mutations (resistant to gefitinib) as well as those harboring the EGFR T790M mutation. Dacomitinib inhibits cell growth and induces apoptosis. Phase 2. |
| Product Details | |
|---|---|
| CAS No. | CAS No. 1110813-31-4 |
| Description | Dacomitinib (PF299804, PF299) is a potent, irreversible pan-ErbB inhibitor, mostly to EGFR with IC50 of 6 nM in a cell-free assay. Dacomitinib inhibits ERBB2 and ERBB4 with IC50 of 45.7 nM and 73.7 nM, respectively. Dacomitinib is effective against NSCLCs with EGFR or ERBB2 mutations (resistant to gefitinib) as well as those harboring the EGFR T790M mutation. Dacomitinib inhibits cell growth and induces apoptosis. Phase 2. |
| Formula | C24H25ClFN5O2 |
| Molecular Weight | 469.94 |
| Storage | 3 years -20°C powder 2 years -80°C in solvent |
| Synonyms | PF299804,PF299 |
| SMILES | COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4 |
| Solubility | DMSO |
| Usage | |
|---|---|
| Storage | 3 years -20°C powder 2 years -80°C in solvent |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.